BACKGROUND: After progression during chemotherapy, persistent ovarian cancer rarely responds to cytotoxic agents. We evaluated the use of adjunctive itraconazole for treating refractory ovarian cancer. PATIENTS AND METHODS: Medical records of patients with ovarian cancer were retrospectively reviewed to select those with a history of platinum and taxane administration, clinical progression within six months of the last platinum administration, continuation of chemotherapy after the first progression during chemotherapy. RESULTS: Among 55 patients, itraconazole in combination with chemotherapy was administered to 19 patients. The median progression-free survival (PFS) was 103 days and 53 days for chemotherapy with and without itraconazole, respectively (p=0.014). The corresponding median overall survival was 642 days and 139 days, respectively (p=0.006). The hazard ratio for PFS was 0.24 (p=0.002) and for overall survival was 0.27 (p=0.006) for therapy with itraconazole. CONCLUSION: Adjunctive itraconazole is promising for patients with refractory ovarian cancer.
BACKGROUND: After progression during chemotherapy, persistent ovarian cancer rarely responds to cytotoxic agents. We evaluated the use of adjunctive itraconazole for treating refractory ovarian cancer. PATIENTS AND METHODS: Medical records of patients with ovarian cancer were retrospectively reviewed to select those with a history of platinum and taxane administration, clinical progression within six months of the last platinum administration, continuation of chemotherapy after the first progression during chemotherapy. RESULTS: Among 55 patients, itraconazole in combination with chemotherapy was administered to 19 patients. The median progression-free survival (PFS) was 103 days and 53 days for chemotherapy with and without itraconazole, respectively (p=0.014). The corresponding median overall survival was 642 days and 139 days, respectively (p=0.006). The hazard ratio for PFS was 0.24 (p=0.002) and for overall survival was 0.27 (p=0.006) for therapy with itraconazole. CONCLUSION: Adjunctive itraconazole is promising for patients with refractory ovarian cancer.
Authors: Sarah A Head; Wei Shi; Liang Zhao; Kirill Gorshkov; Kalyan Pasunooti; Yue Chen; Zhiyou Deng; Ruo-jing Li; Joong Sup Shim; Wenzhi Tan; Thomas Hartung; Jin Zhang; Yingming Zhao; Marco Colombini; Jun O Liu Journal: Proc Natl Acad Sci U S A Date: 2015-12-10 Impact factor: 11.205
Authors: Asmaa Waheed Mohamed; Mohamed Elbassiouny; Dalia Abdelghany Elkhodary; May Ahmed Shawki; Amr Shafik Saad Journal: Med Oncol Date: 2021-02-09 Impact factor: 3.064
Authors: Wei Zhang; Ankur S Bhagwath; Zeeshan Ramzan; Taylor A Williams; Indhumathy Subramaniyan; Vindhya Edpuganti; Raja Reddy Kallem; Kerry B Dunbar; Peiguo Ding; Ke Gong; Samuel A Geurkink; Muhammad S Beg; James Kim; Qiuyang Zhang; Amyn A Habib; Sung-Hee Choi; Ritu Lapsiwala; Gayathri Bhagwath; Jonathan E Dowell; Shelby D Melton; Chunfa Jie; William C Putnam; Thai H Pham; David H Wang Journal: Mol Cancer Ther Date: 2021-08-10 Impact factor: 6.261
Authors: Thiago S Lima; Luciano O Souza; Diego Iglesias-Gato; Johanna Elversang; Flemming Steen Jørgensen; Tuula Kallunki; Martin A Røder; Klaus Brasso; José M A Moreira Journal: Front Pharmacol Date: 2022-06-03 Impact factor: 5.988